Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now !

Asthma Pipeline Insight

DelveInsight’s, “Asthma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Asthma Understanding

Asthma: Overview

Asthma is a long-term condition affecting children and adults. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath and chest tightness. These symptoms are intermittent and are often worse at night or during exercise. Other common “triggers” can make asthma symptoms worse. Triggers vary from person to person, but can include viral infections (colds), dust, smoke, fumes, changes in the weather, grass and tree pollen, animal fur and feathers, strong soaps, and perfume. Asthma is often under-diagnosed and under-treated, particularly in low- and middle-income countries. People with under-treated asthma can suffer sleep disturbance, tiredness during the day, and poor concentration. Asthma sufferers and their families may miss school and work, with financial impact on the family and wider community. If symptoms are severe, people with asthma may need to receive emergency health care and they may be admitted to hospital for treatment and monitoring. In the most severe cases, asthma can lead to death.


"Asthma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Asthma pipeline landscape is provided which includes the disease overview and Asthma treatment guidelines. The assessment part of the report embraces, in depth Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Asthma.

Asthma Emerging Drugs Chapters

This segment of the Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Asthma Emerging Drugs


Tezepelumab: Amgen

Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults. Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.


Depemokimab: GlaxoSmithKline

Depemokimab (formerly GSK 3511294) is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by GlaxoSmithKline. Currently, it is in Phase III stage of clinical trial evaluation.

Further product details are provided in the report……..

Asthma: Therapeutic Assessment

This segment of the report provides insights about the different Asthma drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Asthma

There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. preregistration include, Amgen.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Asthma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Asthma therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Asthma drugs.

Asthma Report Insights

  • Asthma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Asthma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Asthma drugs?
  • How many Asthma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Asthma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Asthma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Asthma: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Asthma – DelveInsight’s Analytical Perspective

Late Stage Products (Preregistration)

  • Comparative Analysis

Tezepelumab: Amgen

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

NOV-14: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

STMC 103H: Siolta Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Research programme: A2BR inhibitors : Tarus Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Asthma Key Companies

Asthma Key Products

Asthma- Unmet Needs

Asthma- Market Drivers and Barriers

Asthma- Future Perspectives and Conclusion

Asthma Analyst Views

Asthma Key Companies

Appendix

List of Table

Table 1: Total Products for Asthma

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Asthma

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Amgen

• GlaxoSmithKline

• Equillium

• Viatris

• Synermore Biologics

• Tarus Therapeutics

• Siolta Therapeutics

• Chiesi Farmaceutici

• Regeneron Pharmaceuticals

• EURRUS Biotech

• Palobiofarma SL

• 4D pharma plc

• AB Science

• Pearl Therapeutics

• Avillion

• Novartis

• Celltrion

• AstraZeneca

• Atopix Therapeutics

• Glenmark Pharmaceuticals

• EMS

• Biohaven Pharmaceuticals, Inc.

• Teva Pharmaceutical

• TFF Pharmaceuticals, Inc.

• Shanghai Hengrui Pharmaceutical Co., Ltd.

• Genentech, Inc.

• CSL Behring

• Oneness Biotech Co., Ltd.

• Aldeyra Therapeutics, Inc.

• Shanghai Biomabs Pharmaceutical Co., Ltd.

• Suzhou Connect Biopharmaceuticals, Ltd.

• Kinaset Therapeutics Inc

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

• Evelo Biosciences, Inc

• Atridia Pty Ltd.

• Keymed Biosciences Co.Ltd

Forward to Friend

Need A Quote